SNN logo

Smith & Nephew (SNN) Stock

Profile

Sector:

Healthcare

Country:

United Kingdom

IPO:

16 November 1999

Indexes:

Not included

Description:

Smith & Nephew (SNN) is a global medical technology company that specializes in advanced wound management, orthopedic reconstruction, and sports medicine. They develop innovative products to help improve patient outcomes and support healthcare professionals in delivering effective treatments. Their focus is on healing and enhancing mobility.

Key Details

Price

$25.39

TTM Dividend Yield

2.95%(+1.72% YoY)

Annual Revenue

$5.55 B(+6.40% YoY)

Annual EPS

$0.60(+18.04% YoY)

Beta

0.64

Events Calendar

Earnings

Next earnings date:

Feb 27, 2025

Recent quarterly earnings:

Aug 01, 2024

Recent annual earnings:

Feb 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

Oct 04, 2024
Splits

Next split:

N/A

Recent split:

Oct 15, 2014

Analyst ratings

Recent major analysts updates

05 June '24 UBS
Buy
04 Oct '23 Bernstein
Outperform
04 Mar '22 Redburn Partners
Neutral
30 Apr '21 Canaccord Genuity
Buy
18 Dec '20 Bernstein
Outperform
30 Oct '20 Canaccord Genuity
Buy
07 May '20 CFRA
Hold
21 Feb '20 CFRA
Hold
12 Nov '19 Bernstein
Outperform
25 Apr '19 Canaccord Genuity
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Big investors call for break-up of Smith & Nephew, FT reports
Big investors call for break-up of Smith & Nephew, FT reports
Big investors call for break-up of Smith & Nephew, FT reports
SNN
reuters.com14 November 2024

Three major investors are pushing medical device maker Smith & Nephew to consider a break-up of the business, the Financial Times reported on Thursday, citing shareholders.

Smith & Nephew: Ready To Reap Demographic, Turnaround Dividends
Smith & Nephew: Ready To Reap Demographic, Turnaround Dividends
Smith & Nephew: Ready To Reap Demographic, Turnaround Dividends
SNN
seekingalpha.com10 November 2024

Smith & Nephew's Q3 results led to a 13% share price drop due to reduced FY24 guidance, mainly from lower demand in China. Despite short-term challenges, long-term fundamentals remain strong, presenting a buying opportunity at current lower prices. The company's 12-point plan aims to boost growth and margins, focusing on orthopedics, productivity, and accelerating growth in advanced wound management and sports medicine.

Smith & Nephew plc (SNN) Q3 2024 Earnings Conference Call Transcript
Smith & Nephew plc (SNN) Q3 2024 Earnings Conference Call Transcript
Smith & Nephew plc (SNN) Q3 2024 Earnings Conference Call Transcript
SNN
seekingalpha.com02 November 2024

Smith & Nephew plc (NYSE:SNN ) Q3 2024 Earnings Conference Call October 31, 2024 4:30 AM ET Company Participants Deepak Nath - CEO & Director John Rogers - CFO & Executive Director Conference Call Participants Jack Reynolds-Clark - RBC Capital Management David Adlington - J.P. Morgan Hassan Al-Wakeel - Barclays Robert Davies - Morgan Stanley Richard Felton - Goldman Sachs Graham Doyle - UBS Lisa Clive - Bernstein Julien Dormois - Jefferies Deepak Nath Good morning, and welcome to the Smith & Nephew third quarter trading update.

Smith & Nephew slashes annual revenue forecast on weak China
Smith & Nephew slashes annual revenue forecast on weak China
Smith & Nephew slashes annual revenue forecast on weak China
SNN
reuters.com31 October 2024

British medical equipment maker Smith & Nephew cut its annual underlying revenue growth forecast on Thursday to 4.5% from the previous outlook range of 5% to 6%, primarily hurt by challenges in its surgical businesses in China.

SNN Stock May Gain Following the Co-Marketing Deal With JointVue
SNN Stock May Gain Following the Co-Marketing Deal With JointVue
SNN Stock May Gain Following the Co-Marketing Deal With JointVue
SNN
zacks.com15 October 2024

Smith & Nephew and JointVue announce a co-marketing agreement for the latter's OrthoSonic 3D Surgery Planning Technology.

SNN Boosts Knee Revision Surgery With Its LEGION Hinged Knee System
SNN Boosts Knee Revision Surgery With Its LEGION Hinged Knee System
SNN Boosts Knee Revision Surgery With Its LEGION Hinged Knee System
SNN
zacks.com11 October 2024

Smith & Nephew introduces the LEGION Hinged Knee System with OXINIUM Technology, elevating knee revision surgery through innovation.

Smith+Nephew partners with JointVue™ for Ultrasound preoperative planning in robotics-assisted surgery
Smith+Nephew partners with JointVue™ for Ultrasound preoperative planning in robotics-assisted surgery
Smith+Nephew partners with JointVue™ for Ultrasound preoperative planning in robotics-assisted surgery
SNN
globenewswire.com09 October 2024

Patented technology further personalizes total knee arthroplasty for surgeons and patients Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it has signed a co-marketing agreement with JointVue for its patented OrthoSonic™ 3D Surgery Planning Technology – the only ultrasound device currently on the market to deliver 3D preoperative planning. JointVue's technology allows surgeons using Smith+Nephew's CORI◊ Surgical System for robotic-assisted knee arthroplasty to create a personalized surgical plan, which may provide opportunities to improve patient satisfaction and operating room efficiency.

SNN Stock Rises on the Completion of First Case With CATALYSTEM System
SNN Stock Rises on the Completion of First Case With CATALYSTEM System
SNN Stock Rises on the Completion of First Case With CATALYSTEM System
SNN
zacks.com20 September 2024

Smith & Nephew announces the completion of the first case using the CATALYSTEM Primary Hip System.

First cases using Smith+Nephew's new CATALYSTEM™ Primary Hip System completed; surgeons hail precision, efficiency and reproducibility
First cases using Smith+Nephew's new CATALYSTEM™ Primary Hip System completed; surgeons hail precision, efficiency and reproducibility
First cases using Smith+Nephew's new CATALYSTEM™ Primary Hip System completed; surgeons hail precision, efficiency and reproducibility
SNN
globenewswire.com18 September 2024

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces promising surgeon feedback from the first completed cases utilizing its new CATALYSTEM Primary Hip System. Designed to address the evolving demands of primary hip surgery - including the increased adoption of anterior approach procedures – the CATALYSTEM Primary Hip System features a triple-taper stem design with uniform proximal loading.1  The reduced distal stem geometry and shorter lengths are ideal for anterior approach but suitable for all approaches.2

SNN Stock Declines Despite the Launch of Its Patient-Matched Guides
SNN Stock Declines Despite the Launch of Its Patient-Matched Guides
SNN Stock Declines Despite the Launch of Its Patient-Matched Guides
SNN
zacks.com13 September 2024

Smith & Nephew announces the launch of its TOTAL ANKLE Patient-Matched Guides to plan and perform total ankle replacement procedures.

FAQ

  • What is the primary business of Smith & Nephew?
  • What is the ticker symbol for Smith & Nephew?
  • Does Smith & Nephew pay dividends?
  • What sector is Smith & Nephew in?
  • What industry is Smith & Nephew in?
  • What country is Smith & Nephew based in?
  • When did Smith & Nephew go public?
  • Is Smith & Nephew in the S&P 500?
  • Is Smith & Nephew in the NASDAQ 100?
  • Is Smith & Nephew in the Dow Jones?
  • When was Smith & Nephew's last earnings report?
  • When does Smith & Nephew report earnings?
  • Should I buy Smith & Nephew stock now?

What is the primary business of Smith & Nephew?

Smith & Nephew (SNN) is a global medical technology company that specializes in advanced wound management, orthopedic reconstruction, and sports medicine. They develop innovative products to help improve patient outcomes and support healthcare professionals in delivering effective treatments. Their focus is on healing and enhancing mobility.

What is the ticker symbol for Smith & Nephew?

The ticker symbol for Smith & Nephew is NYSE:SNN

Does Smith & Nephew pay dividends?

Yes, Smith & Nephew pays dividends. The last payment was $0.29, with an ex-dividend date on 04 October 2024

What sector is Smith & Nephew in?

Smith & Nephew is in the Healthcare sector

What industry is Smith & Nephew in?

Smith & Nephew is in the Medical Devices industry

What country is Smith & Nephew based in?

Smith & Nephew is headquartered in United Kingdom

When did Smith & Nephew go public?

Smith & Nephew's initial public offering (IPO) was on 16 November 1999

Is Smith & Nephew in the S&P 500?

No, Smith & Nephew is not included in the S&P 500 index

Is Smith & Nephew in the NASDAQ 100?

No, Smith & Nephew is not included in the NASDAQ 100 index

Is Smith & Nephew in the Dow Jones?

No, Smith & Nephew is not included in the Dow Jones index

When was Smith & Nephew's last earnings report?

Smith & Nephew's most recent earnings report was on 1 August 2024

When does Smith & Nephew report earnings?

The next expected earnings date for Smith & Nephew is 27 February 2025

Should I buy Smith & Nephew stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions